[
  {
    "ts": null,
    "headline": "Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?",
    "summary": "One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.",
    "url": "https://finnhub.io/api/news?id=43dfffc63e2e8b464fe03aee016a938afabd41794cea74fdc864a3522eb66493",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731355200,
      "headline": "Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?",
      "id": 131292813,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.",
      "url": "https://finnhub.io/api/news?id=43dfffc63e2e8b464fe03aee016a938afabd41794cea74fdc864a3522eb66493"
    }
  },
  {
    "ts": null,
    "headline": "Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.",
    "summary": "Novo drug CagriSema, which combines semaglutide with cagrilintide, could help patients lose 25% of their body weight.",
    "url": "https://finnhub.io/api/news?id=a1ee37457554cc9c64f3f82ad5604bf08cc5bdec7d5468f2b16a8813ae4e9ec9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731345600,
      "headline": "Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.",
      "id": 131289356,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo drug CagriSema, which combines semaglutide with cagrilintide, could help patients lose 25% of their body weight.",
      "url": "https://finnhub.io/api/news?id=a1ee37457554cc9c64f3f82ad5604bf08cc5bdec7d5468f2b16a8813ae4e9ec9"
    }
  },
  {
    "ts": null,
    "headline": "NVS or LLY: Which Is the Better Value Stock Right Now?",
    "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=e932c622e660b7ae640adf9a0b413f4fbff329de09395df7493d1d42861b2601",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731343215,
      "headline": "NVS or LLY: Which Is the Better Value Stock Right Now?",
      "id": 131290199,
      "image": "https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=e932c622e660b7ae640adf9a0b413f4fbff329de09395df7493d1d42861b2601"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=c5dad9a935635863a2efe2fcc9d5593521896b67d7a2a2f4f7ed39bb325c8f74",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731342780,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 131413518,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=c5dad9a935635863a2efe2fcc9d5593521896b67d7a2a2f4f7ed39bb325c8f74"
    }
  },
  {
    "ts": null,
    "headline": "3 US Stocks Estimated Up To 31.4% Below Intrinsic Value",
    "summary": "As the U.S. stock market continues to reach record highs, fueled by a post-election rally and optimism surrounding potential policy changes, investors are keenly focused on identifying opportunities that may still be undervalued amidst this bullish environment. In such a thriving market, finding stocks trading below their intrinsic value can offer significant potential for growth as these companies may not yet reflect their full worth in the current pricing landscape.",
    "url": "https://finnhub.io/api/news?id=316f65534c00fb920659cafc5b3225d7b06d9023c91df86c7ba26e2d7a88fab4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731319624,
      "headline": "3 US Stocks Estimated Up To 31.4% Below Intrinsic Value",
      "id": 131285422,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8045a103f8959173903f7a11497803b2",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the U.S. stock market continues to reach record highs, fueled by a post-election rally and optimism surrounding potential policy changes, investors are keenly focused on identifying opportunities that may still be undervalued amidst this bullish environment. In such a thriving market, finding stocks trading below their intrinsic value can offer significant potential for growth as these companies may not yet reflect their full worth in the current pricing landscape.",
      "url": "https://finnhub.io/api/news?id=316f65534c00fb920659cafc5b3225d7b06d9023c91df86c7ba26e2d7a88fab4"
    }
  },
  {
    "ts": null,
    "headline": "Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies",
    "summary": "Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is rated as a Speculative Buy.",
    "url": "https://finnhub.io/api/news?id=81698e5f6b63a759dfe2a39782ab914d776ae98353730a41c8bdb9fd35ec7ce0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731298369,
      "headline": "Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies",
      "id": 131282090,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2025836701/image_2025836701.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is rated as a Speculative Buy.",
      "url": "https://finnhub.io/api/news?id=81698e5f6b63a759dfe2a39782ab914d776ae98353730a41c8bdb9fd35ec7ce0"
    }
  }
]